<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="2" iati-activities:version="2.03" xml:lang="EN" xmlns:gavi="http://gavi.org/" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>47122-NPL-TCA</iati-identifier>
  <reporting-org ref="47122" type="40">
   <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Nepal: Targeted country assistance</narrative>
   <narrative xml:lang="FR">N&#xE9;pal (le): Aide cibl&#xE9;e aux pays</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="FR">Plans d&#x2019;assistance technique cibl&#xE9;e aux pays L&#x2019;assistance technique cibl&#xE9;e aux pays (TCA) est octroy&#xE9;e sous forme de ressources destin&#xE9;es aux partenaires pr&#xE9;sents dans les pays. La TCA est un &#xE9;l&#xE9;ment du cadre d&#x2019;engagement avec les partenaires (PEF) de Gavi. Le plan de TCA d&#x2019;un pays est &#xE9;tablie selon les besoins exprim&#xE9;s du dit pays lors de l&#x2019;&#xE9;valuation conjointe. Un plan comprend une liste d&#x2019;activit&#xE9;s, d&#x2019;&#xE9;tapes cl&#xE9;s, et un budget pour une ann&#xE9;e dite.  L&#x2019;assistance technique est un soutien non financier fourni par des sp&#xE9;cialistes. Elle peut rev&#xEA;tir plusieurs formes : partage d&#x2019;information et de savoir-faire, formation et services-conseils.

L&#x2019;assistance technique fournie dans le cadre du PEF est appel&#xE9;e aide cibl&#xE9;e aux pays. Ce type de soutien vise principalement &#xE0; payer le personnel bas&#xE9; en permanence dans les bureaux pays des partenaires. Il repose sur la demande et les besoins identifi&#xE9;s par les pays eux-m&#xEA;mes.</narrative>
   <narrative xml:lang="EN">Targeted country assistance (TCA) are resources provided to in-country partners under Gavi&#x2019;s partners&#x2019; engagement framework (PEF). A country&#x2019;s TCA plan is based on needs expressed by the country during the joint appraisal discussions. It includes sets of activities, milestones and budget for a given year.Technical assistance is non-financial support provided by specialists. It can take the form of sharing information and expertise, training and consulting services.

The technical assistance provided through PEF is called targeted country assistance (TCA). This type of support mainly consists of staff permanently based in partners&#x2019; country offices. It is based on the demand and needs identified by the countries themselves.</narrative>
  </description>
  <participating-org role="4">
   <narrative xml:lang="EN">CDC Foundation</narrative>
  </participating-org>
  <participating-org role="4">
   <narrative xml:lang="EN">Centers for Disease Control and Prevention</narrative>
  </participating-org>
  <participating-org ref="47122" role="1" type="40">
   <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
  </participating-org>
  <participating-org ref="47122" role="3" type="40">
   <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
  </participating-org>
  <participating-org role="4" type="10">
   <narrative xml:lang="EN">The Government of Nepal</narrative>
  </participating-org>
  <participating-org ref="XM-DAC-41122" role="4" type="40">
   <narrative xml:lang="EN">United Nations Children&apos;s Fund (UNICEF)</narrative>
  </participating-org>
  <participating-org ref="XI-GRID-grid.5510.1" role="4" type="80">
   <narrative xml:lang="EN">University of Oslo</narrative>
  </participating-org>
  <participating-org ref="XM-DAC-928" role="4" type="40">
   <narrative xml:lang="EN">World Health Organisation (WHO)</narrative>
  </participating-org>
  <other-identifier ref="47122" type="B1">
   <owner-org ref="47122">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </owner-org>
  </other-identifier>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2019-01-01" type="1"></activity-date>
  <activity-date iso-date="2019-01-01" type="2"></activity-date>
  <activity-date iso-date="2022-12-31" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </organisation>
   <email>info@gavi.org</email>
   <website>http://www.gavi.org/</website>
  </contact-info>
  <activity-scope code="4"></activity-scope>
  <recipient-country code="NP" percentage="100"></recipient-country>
  <location>
   <location-reach code="1"></location-reach>
   <location-id code="NP" vocabulary="A4"></location-id>
   <name>
    <narrative xml:lang="EN">Kathmandu</narrative>
   </name>
   <administrative code="NP" vocabulary="A4"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>27.70169 85.3206</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="2"></location-class>
  </location>
  <sector code="TCA" percentage="100" vocabulary="99">
   <narrative xml:lang="EN">Targeted country assistance</narrative>
  </sector>
  <sector code="12250" percentage="100" vocabulary="1"></sector>
  <tag code="1" vocabulary="2"></tag>
  <tag code="10" vocabulary="2"></tag>
  <tag code="11" vocabulary="2"></tag>
  <tag code="13" vocabulary="2"></tag>
  <tag code="16" vocabulary="2"></tag>
  <tag code="17" vocabulary="2"></tag>
  <tag code="2" vocabulary="2"></tag>
  <tag code="3" vocabulary="2"></tag>
  <tag code="4" vocabulary="2"></tag>
  <tag code="5" vocabulary="2"></tag>
  <tag code="7" vocabulary="2"></tag>
  <tag code="8" vocabulary="2"></tag>
  <tag code="9" vocabulary="2"></tag>
  <policy-marker code="1" significance="2" vocabulary="1"></policy-marker>
  <policy-marker code="9" significance="2" vocabulary="1"></policy-marker>
  <collaboration-type code="2"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="2" type="2">
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-31"></period-end>
   <value currency="USD" value-date="2022-03-30">940430</value>
  </budget>
  <budget status="2" type="2">
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-31"></period-end>
   <value currency="USD" value-date="2022-03-30">1203102</value>
  </budget>
  <budget status="2" type="2">
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-12-31"></period-end>
   <value currency="USD" value-date="2022-03-30">678488</value>
  </budget>
  <budget status="2" type="2">
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-31"></period-end>
   <value currency="USD" value-date="2022-03-30">46750.72</value>
  </budget>
  <budget status="2" type="2">
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-31"></period-end>
   <value currency="USD" value-date="2022-03-30">46750.72</value>
  </budget>
  <capital-spend percentage="0"></capital-spend>
  <transaction ref="NPLPEF-TCA-CDC2019">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-01-01"></transaction-date>
   <value currency="USD" value-date="2019-01-01">10000</value>
   <description>
    <narrative xml:lang="EN">2019 Operational budget for PEF-TCA-CDC (Centers for Disease Control and Prevention)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Centers for Disease Control and Prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-CDC FOUND2019">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-01-01"></transaction-date>
   <value currency="USD" value-date="2019-01-01">28000</value>
   <description>
    <narrative xml:lang="EN">2019 Operational budget for PEF-TCA-CDC FOUND (CDC Foundation)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">CDC Foundation</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-CEPA2019">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-01-01"></transaction-date>
   <value currency="USD" value-date="2019-01-01">88503</value>
   <description>
    <narrative xml:lang="EN">2019 Operational budget for PEF-TCA-CEPA</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-UNI OF OSLO2019">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-01-01"></transaction-date>
   <value currency="USD" value-date="2019-01-01">8594</value>
   <description>
    <narrative xml:lang="EN">2019 Operational budget for PEF-TCA-UNI OF OSLO (University of Oslo)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org type="80">
    <narrative xml:lang="EN">University of Oslo</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-UNIC2019">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-01-01"></transaction-date>
   <value currency="USD" value-date="2019-01-01">345600</value>
   <description>
    <narrative xml:lang="EN">2019 Operational budget for PEF-TCA-UNIC (United Nations Children&apos;s Fund (UNICEF))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org type="40">
    <narrative xml:lang="EN">United Nations Children&apos;s Fund (UNICEF)</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-WHO2019">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-01-01"></transaction-date>
   <value currency="USD" value-date="2019-01-01">459733</value>
   <description>
    <narrative xml:lang="EN">2019 Operational budget for PEF-TCA-WHO (World Health Organisation (WHO))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org type="40">
    <narrative xml:lang="EN">World Health Organisation (WHO)</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-CDC2020">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-01-01"></transaction-date>
   <value currency="USD" value-date="2020-01-01">90000</value>
   <description>
    <narrative xml:lang="EN">2020 Operational budget for PEF-TCA-CDC (Centers for Disease Control and Prevention)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Centers for Disease Control and Prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-CEPA2020">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-01-01"></transaction-date>
   <value currency="USD" value-date="2020-01-01">0</value>
   <description>
    <narrative xml:lang="EN">2020 Operational budget for PEF-TCA-CEPA</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-UNI OF OSLO2020">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-01-01"></transaction-date>
   <value currency="USD" value-date="2020-01-01">18804</value>
   <description>
    <narrative xml:lang="EN">2020 Operational budget for PEF-TCA-UNI OF OSLO (University of Oslo)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org type="80">
    <narrative xml:lang="EN">University of Oslo</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-UNIC2020">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-01-01"></transaction-date>
   <value currency="USD" value-date="2020-01-01">720155</value>
   <description>
    <narrative xml:lang="EN">2020 Operational budget for PEF-TCA-UNIC (United Nations Children&apos;s Fund (UNICEF))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org type="40">
    <narrative xml:lang="EN">United Nations Children&apos;s Fund (UNICEF)</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-WHO2020">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-01-01"></transaction-date>
   <value currency="USD" value-date="2020-01-01">374143</value>
   <description>
    <narrative xml:lang="EN">2020 Operational budget for PEF-TCA-WHO (World Health Organisation (WHO))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org type="40">
    <narrative xml:lang="EN">World Health Organisation (WHO)</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-CDC FOUND2021">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-01-01"></transaction-date>
   <value currency="USD" value-date="2021-01-01">92960</value>
   <description>
    <narrative xml:lang="EN">2021 Operational budget for PEF-TCA-CDC FOUND (CDC Foundation)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">CDC Foundation</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-UNI OF OSLO2021">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-01-01"></transaction-date>
   <value currency="USD" value-date="2021-01-01">50651</value>
   <description>
    <narrative xml:lang="EN">2021 Operational budget for PEF-TCA-UNI OF OSLO (University of Oslo)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org type="80">
    <narrative xml:lang="EN">University of Oslo</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-UNIC2021">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-01-01"></transaction-date>
   <value currency="USD" value-date="2021-01-01">244080</value>
   <description>
    <narrative xml:lang="EN">2021 Operational budget for PEF-TCA-UNIC (United Nations Children&apos;s Fund (UNICEF))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org type="40">
    <narrative xml:lang="EN">United Nations Children&apos;s Fund (UNICEF)</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="NPLPEF-TCA-WHO2021">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-01-01"></transaction-date>
   <value currency="USD" value-date="2021-01-01">290797</value>
   <description>
    <narrative xml:lang="EN">2021 Operational budget for PEF-TCA-WHO (World Health Organisation (WHO))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org type="40">
    <narrative xml:lang="EN">World Health Organisation (WHO)</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="9900000967">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-03-31"></transaction-date>
   <value currency="USD" value-date="2019-03-31">10000</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-CDC (Centers for Disease Control and Prevention)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Centers for Disease Control and Prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="5100001736">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-04-29"></transaction-date>
   <value currency="USD" value-date="2020-04-29">90000</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-CDC (Centers for Disease Control and Prevention)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Centers for Disease Control and Prevention</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="9900000968">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-03-31"></transaction-date>
   <value currency="USD" value-date="2019-03-31">28000</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-CDC FOUND (CDC Foundation)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">CDC Foundation</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="5100002631">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-06-08"></transaction-date>
   <value currency="USD" value-date="2021-06-08">92960</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-CDC FOUND (CDC Foundation)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">CDC Foundation</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="9900001234">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-06-30"></transaction-date>
   <value currency="USD" value-date="2019-06-30">54590</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-CEPA</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
  </transaction>
  <transaction ref="9900001360">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-07-31"></transaction-date>
   <value currency="USD" value-date="2019-07-31">-28390</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-CEPA</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
  </transaction>
  <transaction ref="700001252">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-31"></transaction-date>
   <value currency="USD" value-date="2019-12-31">62303</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-CEPA</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
  </transaction>
  <transaction ref="700000432">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-01-01"></transaction-date>
   <value currency="USD" value-date="2020-01-01">-62303</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-CEPA</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
  </transaction>
  <transaction ref="5100001281">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-04-08"></transaction-date>
   <value currency="USD" value-date="2020-04-08">60392</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-CEPA</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
  </transaction>
  <transaction ref="700000318">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-11-19"></transaction-date>
   <value currency="USD" value-date="2019-11-19">7604</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNI OF OSLO (University of Oslo)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XI-GRID-grid.5510.1" type="80">
    <narrative xml:lang="EN">University of Oslo</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="700001283">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-31"></transaction-date>
   <value currency="USD" value-date="2019-12-31">-513</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNI OF OSLO (University of Oslo)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XI-GRID-grid.5510.1" type="80">
    <narrative xml:lang="EN">University of Oslo</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="5100004005">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-09-30"></transaction-date>
   <value currency="USD" value-date="2020-09-30">804</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNI OF OSLO (University of Oslo)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XI-GRID-grid.5510.1" type="80">
    <narrative xml:lang="EN">University of Oslo</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="5100004212">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-11-10"></transaction-date>
   <value currency="USD" value-date="2020-11-10">2374</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNI OF OSLO (University of Oslo)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XI-GRID-grid.5510.1" type="80">
    <narrative xml:lang="EN">University of Oslo</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="9900000005">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-12-31"></transaction-date>
   <value currency="USD" value-date="2020-12-31">-14651</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNI OF OSLO (University of Oslo)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XI-GRID-grid.5510.1" type="80">
    <narrative xml:lang="EN">University of Oslo</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="9900000007">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-12-31"></transaction-date>
   <value currency="USD" value-date="2020-12-31">14651</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNI OF OSLO (University of Oslo)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XI-GRID-grid.5510.1" type="80">
    <narrative xml:lang="EN">University of Oslo</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="5100000297">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-02-03"></transaction-date>
   <value currency="USD" value-date="2021-02-03">975</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNI OF OSLO (University of Oslo)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XI-GRID-grid.5510.1" type="80">
    <narrative xml:lang="EN">University of Oslo</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="5100004265">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-09-07"></transaction-date>
   <value currency="USD" value-date="2021-09-07">2100</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNI OF OSLO (University of Oslo)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XI-GRID-grid.5510.1" type="80">
    <narrative xml:lang="EN">University of Oslo</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="5100004623">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-09-23"></transaction-date>
   <value currency="USD" value-date="2021-09-23">675</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNI OF OSLO (University of Oslo)</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XI-GRID-grid.5510.1" type="80">
    <narrative xml:lang="EN">University of Oslo</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="9900000969">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-03-31"></transaction-date>
   <value currency="USD" value-date="2019-03-31">345600</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNIC (United Nations Children&apos;s Fund (UNICEF))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XM-DAC-41122" type="40">
    <narrative xml:lang="EN">United Nations Children&apos;s Fund (UNICEF)</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="5100001481">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-04-14"></transaction-date>
   <value currency="USD" value-date="2020-04-14">345600</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNIC (United Nations Children&apos;s Fund (UNICEF))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XM-DAC-41122" type="40">
    <narrative xml:lang="EN">United Nations Children&apos;s Fund (UNICEF)</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="5100005692">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-12-21"></transaction-date>
   <value currency="USD" value-date="2020-12-21">374555</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNIC (United Nations Children&apos;s Fund (UNICEF))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XM-DAC-41122" type="40">
    <narrative xml:lang="EN">United Nations Children&apos;s Fund (UNICEF)</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="5100003306">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-07-13"></transaction-date>
   <value currency="USD" value-date="2021-07-13">244080</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-UNIC (United Nations Children&apos;s Fund (UNICEF))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XM-DAC-41122" type="40">
    <narrative xml:lang="EN">United Nations Children&apos;s Fund (UNICEF)</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="9900000970">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-03-31"></transaction-date>
   <value currency="USD" value-date="2019-03-31">459733</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-WHO (World Health Organisation (WHO))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XM-DAC-928" type="40">
    <narrative xml:lang="EN">World Health Organisation (WHO)</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="5100005691">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-12-21"></transaction-date>
   <value currency="USD" value-date="2020-12-21">374143</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-WHO (World Health Organisation (WHO))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XM-DAC-928" type="40">
    <narrative xml:lang="EN">World Health Organisation (WHO)</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="5100003404">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-07-20"></transaction-date>
   <value currency="USD" value-date="2021-07-20">290797</value>
   <description>
    <narrative xml:lang="EN">Disbursement for PEF-TCA-WHO (World Health Organisation (WHO))</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XM-DAC-928" type="40">
    <narrative xml:lang="EN">World Health Organisation (WHO)</narrative>
   </receiver-org>
  </transaction>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/news/document-library/role-expanded-partners-under-pef-guidance-note">
   <title>
    <narrative xml:lang="EN">Partners&#x2019; engagement framework (PEF)</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Guidance on the role of expanded partners in the provision of targeted country assistance</narrative>
   </description>
   <category code="A04"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/fr/actualites/librarie-de-documents/directives-concernant-le-processus-mis-en-place-au-titre-de-laide">
   <title>
    <narrative xml:lang="EN">Directives concernant le processus mis en place au titre de l&#x2019;aide cibl&#xE9;e aux pays dans le cadre du PEF</narrative>
   </title>
   <category code="A04"></category>
   <language code="FR"></language>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/fr/actualites/librarie-de-documents/targeted-country-assistance-plan-nepal-2017">
   <title>
    <narrative xml:lang="EN">Targeted country assistance plan Nepal 2017</narrative>
   </title>
   <category code="A02"></category>
   <category code="A05"></category>
   <language code="EN"></language>
   <document-date iso-date="2017-12-31"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/news/document-library/targeted-country-assistance-plan-nepal-2017">
   <title>
    <narrative xml:lang="EN">Targeted country assistance plan Nepal 2017</narrative>
   </title>
   <category code="A02"></category>
   <category code="A05"></category>
   <language code="EN"></language>
   <document-date iso-date="2017-12-31"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/fr/actualites/librarie-de-documents/targeted-country-assistance-plan-nepal-2018">
   <title>
    <narrative xml:lang="EN">Targeted country assistance plan Nepal 2018</narrative>
   </title>
   <category code="A02"></category>
   <category code="A05"></category>
   <language code="EN"></language>
   <document-date iso-date="2018-12-31"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/news/document-library/targeted-country-assistance-plan-nepal-2018">
   <title>
    <narrative xml:lang="EN">Targeted country assistance plan Nepal 2018</narrative>
   </title>
   <category code="A02"></category>
   <category code="A05"></category>
   <language code="EN"></language>
   <document-date iso-date="2018-12-31"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/fr/actualites/librarie-de-documents/targeted-country-assistance-plan-nepal-2019">
   <title>
    <narrative xml:lang="EN">Targeted Country Assistance Plan Nepal 2019</narrative>
   </title>
   <category code="A02"></category>
   <category code="A05"></category>
   <language code="EN"></language>
   <document-date iso-date="2019-12-31"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/news/document-library/targeted-country-assistance-plan-nepal-2019">
   <title>
    <narrative xml:lang="EN">Targeted Country Assistance Plan Nepal 2019</narrative>
   </title>
   <category code="A02"></category>
   <category code="A05"></category>
   <language code="EN"></language>
   <document-date iso-date="2019-12-31"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/news/document-library/targeted-country-assistance-plan-nepal-2020">
   <title>
    <narrative xml:lang="EN">Targeted Country Assistance Plan Nepal 2020</narrative>
   </title>
   <category code="A02"></category>
   <category code="A05"></category>
   <language code="EN"></language>
   <document-date iso-date="2020-07-13"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/news/document-library/targeted-country-assistance-plan-nepal-2021">
   <title>
    <narrative xml:lang="EN">Targeted Country Assistance Plan Nepal 2021</narrative>
   </title>
   <category code="A02"></category>
   <category code="A05"></category>
   <language code="EN"></language>
   <document-date iso-date="2021-07-27"></document-date>
  </document-link>
  <document-link format="TEXT/HTML" url="https://www.gavi.org/fr/programmes-et-impact/types-de-soutien/pef">
   <title>
    <narrative xml:lang="EN">Cadre d&apos;engagement avec les partenaires</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">A travers le cadre d&#x2019;engagement avec les partenaires, les partenaires de l&#x2019;Alliance du Vaccin soutiennent les activit&#xE9;s de vaccination au niveau national</narrative>
   </description>
   <category code="A12"></category>
   <language code="FR"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://www.gavi.org/types-support/pef/targeted-country-assistance">
   <title>
    <narrative xml:lang="EN">About targeted country assistance</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Gavi&#x2019;s targeted country assistance aims to share our partners&#x2019; specialist skills with the countries we support</narrative>
   </description>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://www.gavi.org/fr/types-de-soutien/pef/aide-ciblee-aux-pays">
   <title>
    <narrative xml:lang="EN">&#xC0; propos de l&#x2019;aide cibl&#xE9;e aux pays</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">L&#x2019;aide cibl&#xE9;e aux pays de Gavi vise &#xE0; partager les comp&#xE9;tences sp&#xE9;cialis&#xE9;es de nos partenaires avec les pays que nous soutenons</narrative>
   </description>
   <category code="A12"></category>
   <language code="FR"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://www.gavi.org/programmes-impact/types-support/pef">
   <title>
    <narrative xml:lang="EN">Partners&apos; engagement framework</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Through the partners&#x2019; engagement framework, Vaccine Alliance partners support countries&#x2019; immunisation activities</narrative>
   </description>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
  <related-activity ref="47122-NPL" type="1"></related-activity>
  <conditions attached="1">
   <condition type="2">
    <narrative xml:lang="EN">Conditions are detailed in the Partners&#x2019; engagement framework</narrative>
    <narrative xml:lang="FR">Les conditions sont d&#xE9;taill&#xE9;es dans le cadre d&apos;engagement des partenaires</narrative>
   </condition>
  </conditions>
  <result type="1">
   <title>
    <narrative xml:lang="EN">UNICEF : Supply chain</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">[Y/N] Strategic planning documentation (EVM-IP, CIP, cold chain rehabilitation plan) supported and submitted to MoH, incorporating VfM, sustainability and zero-dose considerations (as applicable)</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical assistance to develop and support the implementation and monitoring of National Immunization Supply and Cold Chain Road map. Capacity building of Central Cold Room Cold Chain Key Persons and pool of cold chain training facilitators as well as development of simplified job aids for cold chain and effective vaccine management improvement plan implementation (Central, Karnali, Sudurpaschim, Province 2 and Province 4)">
      <location ref="NP"></location>
     </target>
     <actual value="On Track">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Amidst delay due to the COVID-19 pandemic and priority shifting of government to its response, EVM full country assessment by using new tool EVM 2.0 is almost completed. A final draft report including comprehensive implementation plan has been prepared and shared to government for their concurrence. 
Capacitated field level health workers on effective vaccine management. 166 health workers has received EVM training.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">UNICEF</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">EVM assessment conducted and reports ana;lysed and disseminated</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical assistance&#xA0; to conduct&#xA0; EVM assessment">
      <location ref="NP"></location>
     </target>
     <actual value="On Track">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Amidst delay due to the COVID-19 pandemic and priority shifting of government to its response, EVM full country assessment by using new tool EVM 2.0 is ongoing. Field data collection from all sample sites have been completed, verified and information uploaded on the WHO server. A heat map was generated as a basis for the development of improvement plan (IP). Final report of the EVM assessment will be produced by July 2021.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">50 youth clubs identified and trained on social mobilization and Rapid Pro</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Support to 50 municipallites for youth engagement and roll out of Rapid Pro to strengthen social mobiliztion for full immunization">
      <location ref="NP"></location>
     </target>
     <actual value="Minor Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Trainings on social mobilization and Rapid Pro were planned but could not take place due to COVID 19 pandemic. To avoid further delays, UNICEF is coordinating with the municipalities to initiate virtual trainings to these youth clubs. About 30 youth clubs with 600 members in total are expected to be trained on social mobilization for immunization as well as orientation on Rapid Pro by December 2021</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">CDC</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Initation of surveillance</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Assessment of impact and effectiveness of rotavirus vaccine in Nepal">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Completed - Rotavirus surveillance has been initated in Nepal.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">WHO</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">3.3 DQSA completed in&#xA0;four districts; 3.4 Immunization Atlas prepared for all 7 Provinces</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="3.Technical support to strengthen RI data to drive high coverage and equity&#xA0;through development of Immunization Atlas and DQSA">
      <location ref="NP"></location>
     </target>
     <actual value="Major Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">DQSA and immunization atlas preparation was included in FY 2019/20 AWPB. However, due to nation-wide MR SIA and selected districts polio campaign in FY 2019/20, program prioritized on preparation and implementation of the SIA. Since then, this activity has been on hold till now due to the ongoing pandemic situation and lock-downs. Given the current situation, this activity may not be possible to do now. Therefore, we request for dropping this activity. We will do our best to have the DQSA completed in coming FY 2021/2022 subject to the pandemic situation, and immunization atlas will be prepared thereafter.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">14.1 fIPV PIE preparations started with development of PIE protocol/proposal</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="14. fIPV PIE completed 6-12 months after introduction">
      <location ref="NP"></location>
     </target>
     <actual value="Re-programmed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">For fIPV PIE activity, minimal cost was included (USD 5000) in TCA with plans to conduct fIPV PIE along with rotavirus vaccine PIE (with shared costs from rotavirus PIE). However, rotavirus vaccine introduction was delayed due to unavailability of the vaccine (global shortage). Rotavirus vaccine was finally introduced in Nepal in July 2020 in the midst of a pandemic. PIE for rotavirus vaccine (including fIPV) is planned in 2021, but the COVID-19 pandemic situation is severe in 2021 compared to 2020. Therefore, fIPV PIE will be conducted with rotavirus or typhoid vaccine PIE depending upon the situation and will be reported accordingly. Since this is minimal value activity to be conducted with other activity (rotavirus or typhoid), we request for re-programming of this activity and same is reported here if acceptable. If not allowed, then the activity is reported as major delay.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">14.2 fIPV PIE completed and report produced</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="14. fIPV PIE completed 6-12 months after introduction">
      <location ref="NP"></location>
     </target>
     <actual value="Re-programmed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">For fIPV PIE activity, minimal cost was included (USD 5000) in TCA with plans to conduct fIPV PIE along with rotavirus vaccine PIE (with shared costs from rotavirus PIE). However, rotavirus vaccine introduction was delayed due to unavailability of the vaccine (global shortage). Rotavirus vaccine was finally introduced in Nepal in July 2020 in the midst of a pandemic. PIE for rotavirus vaccine (including fIPV) is planned in 2021, but the COVID-19 pandemic situation is severe in 2021 compared to 2020. Therefore, fIPV PIE will be conducted with rotavirus or typhoid vaccine PIE depending upon the situation and will be reported accordingly. Since this is minimal value activity to be conducted with other activity (rotavirus or typhoid), we request for re-programming of this activity and same is reported here if acceptable. If not allowed, then the activity is reported as major delay.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Protocol development for MR SIA coverage survey completed before June 2020 and agency identified and hired for survey</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Post MR-SIA coverage evaluation survey as per WHO protocol for a national level&#xA0; estimate.">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">MR SIA was conducted in two phases in 2020. Towards the end of the first phase in March 2020, lock-downs due to COVID-19 pandemic started. The second phase of MR SIA, although initially interrupted due to the lockdown, was completed on 7 July. In 2020, Nepal was probably one of the first countries in the world to complete a vaccination campaign (nation-wide MR SIA and selected district OPV SIA) as well as introduce a new vaccine (rotavirus) in RI. WHO-IPD has provided full technical support for this. As there has been several lock-downs (currently also Nepal is in lock-down) and the COVID-19 pandemic is ongoing, we could not conduct the coverage survey yet. However, now the concept note has been developed and survey agency has been selected, and we are targeting to complete the coverage survey within 2021 at the earliest possible (subject to restrictions due to COVID-19 pandemic). Therefore, for this milestone it is reported as completed now. There are two other separate milestones in relation to the coverage survey completion which will be reported separately.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">WHO : Service Delivery</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">5.2 Concurrent monitoring data is generated every quarter at sub-national/sub-province level and shared at sub-national and national levels for actions.</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="5. Strengthening new vaccine introduction and routine immunization at sub-national level">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Description of progress attached.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">6.2 Independent monitoring completed in at least 15 districts with data provided to central core group for action</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="6. Strengthening/support National Immunization Program through independent monitoring to improve immunization coverage and equity">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Detail about independent monitoring is given in Milestone 5.2 above. In 2021, for routine immunization only, 72 district level exclusive immunization monitoring with 115 visits, 655 health facility level monitoring with 703 visits, 437 immunization session site monitoring with 480 visits, and 5083 children in 568 communities have been monitored till end September 2021. This is a continuous activity.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">5.1 Concurrent monitoring data is generated every quarter at sub-national/sub-province level and shared at sub-national and national levels for actions.</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="5. Strengthening new vaccine introduction and routine immunization at sub-national level">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Please see the attached description of progress</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">6.1 Independent monitoring started at sub-district level with data feeding to central core group and to sub-national level for action</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="6. Strengthening/support National Immunization Program through independent monitoring to improve immunization coverage and equity">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Please see the attached description of progress</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">UNICEF : Demand Promotion &amp; ACSM</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Plan to overcome vaccine demand-related barriers in high risk communities developed</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Implementation and monitoring of National Communication and Social Mobilization Strategy for Routine immunization Nation-wide and at sub-national level">
      <location ref="NP"></location>
     </target>
     <actual value="On Track">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Following the endorsement of the National Communication and Social Mobilization Strategy, Human Centered Design training conducted to 18 participants from National Health Training Center, National Health Education, Information and Communication Center, Nursing and Social Services Division, WHO and Family Welfare Division/Immunization section to understand the vaccine uptake and hesitancy among low coverage area and zero dose community. The journey of health approach used to understand the routine immunization uptake behaviors. The learning from the qualitative research used for developing the targeted work plan to improve the immunization utilization. The major barriers identified were access to the immunization services, ignorant towards the immunization schedule and its importance. Altogether 235 Female community health volunteers from 5 municipalities with low coverage from Sudur-Province trained on revised immunization schedule, interpersonal communication and promotion of RI for under two children. Continuation of Routine immunization services and importance of immunization messages disseminated through radio, television and social media.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Rapid pro reporting mechanism established</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Support to 50 municipallites for youth engagement and roll out of Rapid Pro to strengthen social mobiliztion for full immunization">
      <location ref="NP"></location>
     </target>
     <actual value="Minor Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">More than 5,000 people including youths and adolescent, 35,000 Female community health volunteers are registered in the system for information sharing and data collection. Due to pandemic, training of the youths and adolescents on rapid pro reporting was postponed.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Support to 50 municipallites for youth engagement and roll out of Rapid Pro to strengthen social mobiliztion for full immunization">
      <location ref="NP"></location>
     </target>
     <actual value="Minor Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">More than 5,000 people including youths and adolescent, 35,000 Female community health volunteers are registered in the system for information sharing and data collection. Due to pandemic, training of the youths and adolescents on rapid pro reporting was postponed.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Support to 50 municipallites for youth engagement and roll out of Rapid Pro to strengthen social mobiliztion for full immunization">
      <location ref="NP"></location>
     </target>
     <actual value="Minor Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">More than 5,000 people including youths and adolescent, 35,000 Female community health volunteers are registered in the system for information sharing and data collection. Due to pandemic, training of the youths and adolescents on rapid pro reporting was postponed.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">100&#xA0; local elected representatives and media persons&#xA0;oriented on the immunization act</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Support to 50 municipaliites for advocacy to elected local representations on the immunization act and RI promotion">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">UNICEF provided technical assistance in the development of the advocacy packages for the orientation of both elected representatives and media persons. Both English and Nepal version are endorsed (document attached). The packages are being used for the orientations. With UNICEF support, Family Welfare Division in coordination with Provincial Health Directorates conducted orientation on the Immunization Act to 187 elected representatives and 36 media persons from 50 municipalities.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Support to 50 municipaliites for advocacy to elected local representations on the immunization act and RI promotion">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">UNICEF provided technical assistance in the development of the advocacy packages for the orientation of both elected representatives and media persons. Both English and Nepal version are endorsed (document attached). The packages are being used for the orientations. With UNICEF support, Family Welfare Division in coordination with Provincial Health Directorates conducted orientation on the Immunization Act to 187 elected representatives and 36 media persons from 50 municipalities.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">National Communication and Social Mobilization Strategy for Routine immunization endorsed by the MoHP</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical&#xA0;assistance&#xA0;to develop National communication and social mobilization stratey for Routine Immunization">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">With the wider consultation of relevant stakeholders at federal and provincial levels, National Communication and Social Mobilization Strategy for Routine Immunization has been developed and endorsed by the government.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical&#xA0;assistance&#xA0;to develop National communication and social mobilization stratey for Routine Immunization">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">With the wider consultation of relevant stakeholders at federal and provincial levels, National Communication and Social Mobilization Strategy for Routine Immunization has been developed and endorsed by the government.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">WHO : Programme Implementation/Coverage &amp; Equity</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Progress towards measles elimination and rubella/CRS control and quality VPD surveillance&#xA0;are sustained and achieved timely and routine immunization is strengthened.</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="HR (SSA) for VPD and immunization program- Measles and RI officer (VPD Surveillance Focal Point)">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">COVID-19 pandemic started in the first quarter of 2020 and is still ongoing. There has been several lock-down and currently Nepal is in nation-wide lock-down that started from 29 April 2021 due to the second generalized wave of the pandemic having one of the highest rates. However, cardinal surveillance performance indicators have been maintained. Non-polio AFP rate in 2020 was 2.58 (maintained above the required yearly rate of 2), and in 2021 till mid-May is 1.78 (annualized rate; due to lock-down sample transport to regional lab is pending - current AFP rate is 2.38; post pending sample tests, current non polio AFP rate is expected to also be 2.38). Similarly, non-measles non-rubella rate in 2020 was 3.21 (maintained above the required yearly rate of 2), and in 2021 till mid-May is 4.32 (annualized rate). This is an ongoing activity and the milestone is included in each reporting period, and here the status is reported as completed for this period.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="HR (SSA) for VPD and immunization program- Measles and RI officer (VPD Surveillance Focal Point)">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">COVID-19 pandemic started in the first quarter of 2020 and is still ongoing. There has been several lock-down and currently Nepal is in nation-wide lock-down that started from 29 April 2021 due to the second generalized wave of the pandemic having one of the highest rates. However, cardinal surveillance performance indicators have been maintained. Non-polio AFP rate in 2020 was 2.58 (maintained above the required yearly rate of 2), and in 2021 till mid-May is 1.78 (annualized rate; due to lock-down sample transport to regional lab is pending - current AFP rate is 2.38; post pending sample tests, current non polio AFP rate is expected to also be 2.38). Similarly, non-measles non-rubella rate in 2020 was 3.21 (maintained above the required yearly rate of 2), and in 2021 till mid-May is 4.32 (annualized rate). This is an ongoing activity and the milestone is included in each reporting period, and here the status is reported as completed for this period.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">NVI, RI, SIA, budgeting and financial implementation support is provided at central level and sustained in the context of federalization. (Gavi supported non-pool fund activities and budget for FY 2019/2020 is tracked with timely reporting).</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="HR (staff) for immunization program - Immunization Program Assistant">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">For all Gavi related grants such as VIG (except pool-fund which has separate mechanism) significant technical support was provided for budgeting, activity implementation, as well as for financial reporting. The recent grant support for implementation was for MR SIA and rotavirus vaccine (in 2020). Further, support was provided (in 2021) for inclusion of activities and budget in AWPB 2021/22 for typhoid catch-up campaign (Operations support) and vaccine introduction (VIG) supported by Gavi. The outstanding audit report has recently been submitted by Family Welfare Division to Gavi, which is one of the most important Grant Management Requirements. Full support (technical) was provided towards achieving completion of this.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="HR (staff) for immunization program - Immunization Program Assistant">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">For all Gavi related grants such as VIG (except pool-fund which has separate mechanism) significant technical support was provided for budgeting, activity implementation, as well as for financial reporting. The recent grant support for implementation was for MR SIA and rotavirus vaccine (in 2020). Further, support was provided (in 2021) for inclusion of activities and budget in AWPB 2021/22 for typhoid catch-up campaign (Operations support) and vaccine introduction (VIG) supported by Gavi. The outstanding audit report has recently been submitted by Family Welfare Division to Gavi, which is one of the most important Grant Management Requirements. Full support (technical) was provided towards achieving completion of this.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Concurrent monitoring data is generated every month and sub-national/sub-province level activities for RI and all aspects of NVI is coordinated (Per month at least 4 days of exclusive immunization supervision and monitoring is conducted by each of the 15 SMOs)</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Strengthening new vaccine introduction and routine immunization at sub-national level">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Please see the attached description of progress</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Strengthening new vaccine introduction and routine immunization at sub-national level">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Please see the attached description of progress</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Immunization trainings, monitoring, evaluation and supervision, full immunization will be supported timely and with quality (At least 8 IPCG meetings for immunization monitoring completed for FY 2020/2021)</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="HR (staff) for immunization program - Immunization Monitoring Officer">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">WHO-IPD has supported immunization trainings at all levels, from central level preparation of master trainers, and in provincial training of trainers through central staff, to sub-national level trainings through field staff (SMO network) with central monitoring. Trainings at all sub-national levels for VPD surveillance has been provided. Further, the training for COVID-19 vaccination program now has also been provided at all levels. Numerous monitoring and supervision have been conducted (and reported in detail for other indicators) including continuous RI monitoring at all levels (district, health facility, immunization session, and community). Further, QIA and session site monitoring have been conducted in SIA and for COVID-19 vaccination program. These have been conducted even though the pandemic is ongoing. Currently, IPCG (immunization program core group) due to current context of COVID-19 has been converted to immunization secretariat looking after both RI and COVID-19 vaccination program. At least one meeting per week is conducted. This is a continuous activity and will be reported accordingly in the next milestone as well.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="HR (staff) for immunization program - Immunization Monitoring Officer">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">WHO-IPD has supported immunization trainings at all levels, from central level preparation of master trainers, and in provincial training of trainers through central staff, to sub-national level trainings through field staff (SMO network) with central monitoring. Trainings at all sub-national levels for VPD surveillance has been provided. Further, the training for COVID-19 vaccination program now has also been provided at all levels. Numerous monitoring and supervision have been conducted (and reported in detail for other indicators) including continuous RI monitoring at all levels (district, health facility, immunization session, and community). Further, QIA and session site monitoring have been conducted in SIA and for COVID-19 vaccination program. These have been conducted even though the pandemic is ongoing. Currently, IPCG (immunization program core group) due to current context of COVID-19 has been converted to immunization secretariat looking after both RI and COVID-19 vaccination program. At least one meeting per week is conducted. This is a continuous activity and will be reported accordingly in the next milestone as well.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">WHO : Policy &amp; Regulatory Environment</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Immunization (NIAC/NITAG) and surveillance (NVCMRE, NCCPE) committees involved in immunization monitoring (including reviews and sub-national visits in low-performing areas if required). Monitoring visits through the committee members completed in at least 4&#xA0;province levels and 7 district levels (low-performing) and recommendations submitted to IPCG before June 2021.</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical support to national immunization committees (NIAC, ICC and AEFI committee, etc) and VPDs surveillance committees (NCCPE, NVCMRE, etc), and monitoring of NIP">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Immunization and surveillance committees (NIAC, NVCMRE, NCCPE, AEFI) members have been involved in monitoring including at sub-national level with visits in more than 7 district levels and at least 4 province levels in 2020 and 2021 till date with recommendations to the program. The monitoring includes for RI, SIA, and recently for COVID-19 vaccination campaign as well. This is an ongoing activity but has been affected by COVID-19 pandemic and lock-downs. Even though the milestone is achieved, we will increase monitoring when lock-downs and restrictions are eased.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical support to national immunization committees (NIAC, ICC and AEFI committee, etc) and VPDs surveillance committees (NCCPE, NVCMRE, etc), and monitoring of NIP">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Immunization and surveillance committees (NIAC, NVCMRE, NCCPE, AEFI) members have been involved in monitoring including at sub-national level with visits in more than 7 district levels and at least 4 province levels in 2020 and 2021 till date with recommendations to the program. The monitoring includes for RI, SIA, and recently for COVID-19 vaccination campaign as well. This is an ongoing activity but has been affected by COVID-19 pandemic and lock-downs. Even though the milestone is achieved, we will increase monitoring when lock-downs and restrictions are eased.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">WHO : Vaccine-Specific Support</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">2.2 Timely committee meetings will be held with technical support to make policy recommendations and monitoring on immunization, surveillance and vaccine safety</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="2. Technical support to national immunization committees (NCIP, ICC and AEFI committee, etc) and VPDs surveillance committees (NCCPE, ERC, NVCMRE, etc)">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">In 2020 and 2021, despite COVID-19 pandemic situation and lockdowns, WHO-IPD has provided full technical and secretariat support to immunization and VPD committees (including for COVID-19 vaccination program). In 2020, the following meetings have been conducted: National AEFI Investigation Committee (NAIC, 2), National Immunization Advisory Committee (NIAC, 7), Inter-Agency Coordination Committee (ICC, 2), Expert Review Committee for Polio Case Classification (ERC, 1), National Verification Committee for Measles and Rubella Elimination (NVCMRE, 1), National Certification Committee for Polio Eradication (NCCPE, 1) and 1 joint NVCMRE/NCCPE meetings have been conducted and the National Immunization Program has been supported. Further, in 2021 till date, the following meetings have been conducted: National Immunization Committee (NIC, 1), NAIC (7), NIAC (13), ICC (2), ERC (1), NCCPE (2) and NVCMRE (1). WHO-IPD has provided full technical support also to &apos;COVID-19 Vaccine Advisory Committee of Experts&apos; which is newly constituted by the Ministry of Health and Population, and also to the immunization secretariat. Numerous meetings of these committees have been conducted. This is a continuous activity.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">2.1 Timely committee meetings will be held with technical support to make policy recommendations and monitoring on immunization, surveillance and vaccine safety</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="2. Technical support to national immunization committees (NCIP, ICC and AEFI committee, etc) and VPDs surveillance committees (NCCPE, ERC, NVCMRE, etc)">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">In 2020 and 2021, despite COVID-19 pandemic situation and lockdowns, WHO-IPD has provided full technical and secretariat support to immunization and VPD committees. In 2020, the following meetings have been conducted: National AEFI Investigation Committee (2), National Immunization Advisory Committee (7), Inter-Agency Coordination Committee (2), Expert Review Committee for Polio Case Classification (1), NVCMRE (National Verification Committee for Measles and Rubella Elimination) (1), NCCPE (National Certification Committee for Polio Eradication) (1) and 1 joint NVCMRE/NCCPE meetings have been conducted and the National Immunization Program has been supported. Further, in 2021 till date, the following meetings have been conducted: National AEFI Investigation Committee (6), National Immunization Advisory Committee (7), Inter-Agency Coordination Committee (1), Expert Review Committee for Polio Case Classification (1). WHO-IPD has provided full technical support also to &apos;COVID-19 Vaccine Advisory Committee of Experts&apos; which is newly constituted by the Ministry of Health and Population, and also to the immunization secretariat. Numerous meetings of the committee have been conducted.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Post SIA CES final report available before 31 December 2020</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Post MR-SIA coverage evaluation survey as per WHO protocol for a national level&#xA0; estimate.">
      <location ref="NP"></location>
     </target>
     <actual value="Major Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">MR SIA was conducted in two phases in 2020. Towards the end of the first phase in March 2020, lock-downs due to COVID-19 pandemic started. The second phase of MR SIA, although initially interrupted due to the lockdown, was completed on 7 July. In 2020, Nepal was probably one of the first countries in the world to complete a vaccination campaign (nation-wide MR SIA and selected district OPV SIA) as well as introduce a new vaccine (rotavirus) in RI. WHO-IPD has provided full technical support for this. As there has been several lock-downs (currently also Nepal is in lock-down) and the COVID-19 pandemic is ongoing, we could not conduct the coverage survey yet. However, now the concept note has been developed and survey agency has been selected, and we are targeting to complete the coverage survey within 2021 at the earliest possible (subject to restrictions due to COVID-19 pandemic). It is expected that the final report will be available only in Q1 of 2022.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Post MR-SIA coverage evaluation survey as per WHO protocol for a national level&#xA0; estimate.">
      <location ref="NP"></location>
     </target>
     <actual value="Major Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">MR SIA was conducted in two phases in 2020. Towards the end of the first phase in March 2020, lock-downs due to COVID-19 pandemic started. The second phase of MR SIA, although initially interrupted due to the lockdown, was completed on 7 July. In 2020, Nepal was probably one of the first countries in the world to complete a vaccination campaign (nation-wide MR SIA and selected district OPV SIA) as well as introduce a new vaccine (rotavirus) in RI. WHO-IPD has provided full technical support for this. As there has been several lock-downs (currently also Nepal is in lock-down) and the COVID-19 pandemic is ongoing, we could not conduct the coverage survey yet. However, now the concept note has been developed and survey agency has been selected, and we are targeting to complete the coverage survey within 2021 at the earliest possible (subject to restrictions due to COVID-19 pandemic). It is expected that the final report will be available only in Q1 of 2022.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Post MR-SIA coverage evaluation survey as per WHO protocol for a national level&#xA0; estimate.">
      <location ref="NP"></location>
     </target>
     <actual value="Major Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">MR SIA was conducted in two phases in 2020. Towards the end of the first phase in March 2020, lock-downs due to COVID-19 pandemic started. The second phase of MR SIA, although initially interrupted due to the lockdown, was completed on 7 July. In 2020, Nepal was probably one of the first countries in the world to complete a vaccination campaign (nation-wide MR SIA and selected district OPV SIA) as well as introduce a new vaccine (rotavirus) in RI. WHO-IPD has provided full technical support for this. As there has been several lockdowns both in 2020 and 2021, and the COVID-19 pandemic is ongoing, we could not conduct the coverage survey previously. However, now the coverage survey field work is completed and was done as per latest WHO guideline for campaign coverage survey. Currently, analysis is ongoing, and report is expected to be available in January 2022.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Post SIA CES completed and analysis done</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Post MR-SIA coverage evaluation survey as per WHO protocol for a national level&#xA0; estimate.">
      <location ref="NP"></location>
     </target>
     <actual value="Major Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">MR SIA was conducted in two phases in 2020. Towards the end of the first phase in March 2020, lock-downs due to COVID-19 pandemic started. The second phase of MR SIA, although initially interrupted due to the lockdown, was completed on 7 July. In 2020, Nepal was probably one of the first countries in the world to complete a vaccination campaign (nation-wide MR SIA and selected district OPV SIA) as well as introduce a new vaccine (rotavirus) in RI. WHO-IPD has provided full technical support for this. As there has been several lock-downs (currently also Nepal is in lock-down) and the COVID-19 pandemic is ongoing, we could not conduct the coverage survey yet. However, now the concept note has been developed and survey agency has been selected, and we are targeting to complete the coverage survey within 2021 at the earliest possible (subject to restrictions due to COVID-19 pandemic).</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">1.1 Preparatory work for introduction of TCV completed (guidelines .etc.)</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="1. Technical support for new vaccines introduction (TCV, HPV, PIE for fIPV and RVV) in National Immunization Program">
      <location ref="NP"></location>
     </target>
     <actual value="On Track">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Preparatory work for TCV campaign and introduction in routine immunization is ongoing. Guideline is being written and is scheduled to be completed by 10 December 2021.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">CDC : Health Information Systems (Data)</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Preliminary summary of first year of data</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Assessment of impact and effectiveness of rotavirus vaccine in Nepal">
      <location ref="NP"></location>
     </target>
     <actual value="Minor Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Minor Delays - Testing kit stock-outs and COVID-19 response activities have slowed data cleaning activities within the country which in turn has delayed a summary of the first year of data. Activities continue as able and once on initial round of data cleaning has been conducted, a preliminary summary of the data will be produced.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Assessment of impact and effectiveness of rotavirus vaccine in Nepal">
      <location ref="NP"></location>
     </target>
     <actual value="Minor Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Minor Delays - Testing kit stock-outs and COVID-19 response activities have slowed data cleaning activities within the country which in turn has delayed a summary of the first year of data. Activities continue as able and once on initial round of data cleaning has been conducted, a preliminary summary of the data will be produced.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Assessment of impact and effectiveness of rotavirus vaccine in Nepal">
      <location ref="NP"></location>
     </target>
     <actual value="Minor Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Minor Delays - Testing kit stock-outs and COVID-19 response activities have slowed data cleaning activities within the country which in turn has delayed a summary of the first year of data. Activities continue as able and testing of the backlog of specimens has resumed. Once on initial round of data cleaning has been conducted, a preliminary summary of the data will be produced.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Completion of first round of data cleaning</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Assessment of impact and effectiveness of rotavirus vaccine in Nepal">
      <location ref="NP"></location>
     </target>
     <actual value="Minor Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Minor delays - Surveillance is ongoing but a stock out of ELISA kits for testing of collected specimens has delayed testing. Kits were recently procurred and testing of the backlog of specimens has commenced. Testing has been slowed due to ongoing COVID-19 response acitivities in the country.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">UNICEF : Supply Chain &amp; Procurement</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">National Immunization supply chain action plan endorsed by the MoHP</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical&#xA0;assistance to develop National Immunization supply and cold chain road map">
      <location ref="NP"></location>
     </target>
     <actual value="Major Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Process to initiate developing immunization supply chain (iSC) action plan was halted since the onset of COVID-19 pandemic. Government is still very much focused and giving priority to COVID-19 vaccination because of which process has not accelerated.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical&#xA0;assistance to develop National Immunization supply and cold chain road map">
      <location ref="NP"></location>
     </target>
     <actual value="Major Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Process to initiate developing immunization supply chain (iSC) action plan was halted since the onset of COVID-19 pandemic. Government priority has shifted from executing routine programme to COVID-19 response and COVID-19 vaccination.
Recently, before the second wave of COVID-19 surge, a consultant has been hired to resume and accelerate the process. As of June 2021 an Immunization Specialist is onboard to lead this work.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical&#xA0;assistance to develop National Immunization supply and cold chain road map">
      <location ref="NP"></location>
     </target>
     <actual value="Major Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Process to initiate developing immunization supply chain (iSC) action plan was halted since the onset of COVID-19 pandemic. Government priority has shifted from executing routine programme to COVID-19 response and COVID-19 vaccination.
Recently, before the second wave of COVID-19 surge, a consultant has been hired to resume and accelerate the process. As of June 2021 an Immunization Specialist is onboard to lead this work.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">WHO : Human Resources for Health</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">7.1 Progress towards measles elimination and rubella/CRS control are achieved timely and routine immunization is strengthened.</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="7. HR (staff - SSA) Measles, VPD surveillance and RI support Officer">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">COVID-19 pandemic started in the first quarter of 2020 and is still ongoing. There has been several lock-down and currently Nepal is in nation-wide lock-down that started from 29 April 2021 due to the second generalized wave of the pandemic having one of the highest rates. However, cardinal surveillance performance indicators have been maintained. Non-polio AFP rate in 2020 was 2.58 (maintained above the required yearly rate of 2), and in 2021 till mid-May is 1.78 (annualized rate; due to lock-down sample transport to regional lab is pending - current AFP rate is 2.38; post pending sample tests, current non polio AFP rate is expected to also be 2.38). Similarly, non-measles non-rubella rate in 2020 was 3.21 (maintained above the required yearly rate of 2), and in 2021 till mid-May is 4.32 (annualized rate). This is an ongoing activity and the milestone is included in each reporting period, and here the status is reported as completed for this period.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">7.2 Progress towards measles elimination and rubella/CRS control are achieved timely and routine immunization is strengthened.</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="7. HR (staff - SSA) Measles, VPD surveillance and RI support Officer">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Despite the ongoing COVID-19 pandemic which has affected everything, the cardinal surveillance performance indicators for VPD surveillance have been maintained. Annualized Non-Polio AFP (NP-AFP) rate in 2020 was 2.66, which is above the global standard, and in 2021 the AFP rate is 2.69, which is above the global standard. 71 samples results are pending and is expected soon. Annualized Non-Measles Non-Rubella Rate (NMNR) in 2020 was 3.21 and in 2021 it is maintained at 3.49 (data as of 30 Nov 2021); in both years it is above the required global standard. The administrative coverage of MR1 is 82.3% and MR2 is 80.9% (based on trend, WUENIC coverage will be higher that this), with MR 2 coverage increasing significantly. The gap between MR 1 and MR2 has been significantly reduced now at 1.4% points only. This is a continuous activity.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">9.1 New vaccine introduction, routine immunization, supplementary immunization, budgeting and financial implementation support is provided at central level and sustained in the context of federalization</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="9. HR (staff -SSA) for immunization program - Immunization Program Assistant">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">For all Gavi related grants such as VIG (except pool-fund which has separate mechanism) significant technical support was provided for budgeting, activity implementation, as well as for financial reporting. The recent grant support for implementation was for MR SIA and rotavirus vaccine (in 2020). Further, support was provided (in 2021) for inclusion of activities and budget in AWPB 2021/22 for typhoid catch-up campaign (Operations support) and vaccine introduction (VIG) supported by Gavi. The outstanding audit report has recently been submitted by Family Welfare Division to Gavi, which is one of the most important Grant Management Requirements. Full support (technical) was provided towards achieving completion of this.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">9.2 New vaccine introduction, routine immunization, supplementary immunization, budgeting and financial implementation support is provided at central level and sustained in the context of federalization</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="9. HR (staff -SSA) for immunization program - Immunization Program Assistant">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">For all Gavi related grants such as VIG (except pool-fund which has separate mechanism) significant technical support was provided for budgeting, activity implementation, as well as for financial reporting. The recent grant support for implementation was for MR SIA and rotavirus vaccine (in 2020). Further, support was provided (in 2021) for inclusion of activities and budget in AWPB 2021/22 for typhoid catch-up campaign (Operations support) and vaccine introduction (VIG) supported by Gavi. The outstanding audit report, the main component of Grant Management Requirement, was submitted to Gavi and was accepted/cleared by Gavi. Technical support was provided towards achieving this. This is a continuous activity.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">10.1 Support in data management in immunization and surveillance is provided including achievement of all data related activities in TCA.</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="10. HR (staff -SSA) for immunization program - Data assistant">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Progress is maintained in data management, data work-flow mechanisms, use of software and tools, analysis, data quality improvement, feedback, data triangulation, etc., for both VPD and immunization, and now for COVID-19 vaccination support such as for monitoring data. For VPD surveillance data, developed web-based data management system is in full use. For independent immunization monitoring, data is periodically analyzed using developed tools, and session site monitoring data for COVID-19 vaccination is periodically analyzed and shared. For rotavirus surveillance, developed surveillance data management system and database are in use, and data is checked every month for data quality and feedback is given. HMIS data for both immunization and VPD cases are analyzed periodically and feedback given. WHO-IPD disseminates VPD and immunization data summary to all relevant stakeholders every month. We have developed database for laboratory to link laboratory results and VPD clinical data in real-time and viewing in real-time by staff collecting clinical data (database completed; in discussion now for server space). Development, piloting and implementation of app based (for tablets and mobile platforms) immunization monitoring system was done for MR SIA. The tablet based system for RI monitoring is in development (as reported in Milestone 3.1). Work in this area has been supported by contractors on SSA or other forms of contract. This is an ongoing activity and is included in the next reporting milestone as well and will be reported accordingly.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">10.2 Support in data management in immunization and surveillance is provided including achievement of all data related activities in TCA.</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="10. HR (staff -SSA) for immunization program - Data assistant">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Progress is maintained in data management, data work-flow mechanisms, use of software and tools, analysis, data quality improvement, feedback, data triangulation, etc., for both VPD and immunization, and now for COVID-19 vaccination support such as for monitoring data. For VPD surveillance data, developed web-based data management system is in full use. For independent immunization monitoring, data is periodically analyzed using developed tools, and session site monitoring data for COVID-19 vaccination is periodically analyzed and shared. For rotavirus surveillance, developed surveillance data management system and database are in use, and data is checked every month for data quality and feedback is given. HMIS data for both immunization and VPD cases are analyzed periodically and feedback given. WHO-IPD disseminates VPD and immunization data summary to all relevant stakeholders every month. We have developed database for laboratory to link laboratory results and VPD clinical data in real-time and viewing in real-time by staff collecting clinical data (database completed; in discussion now for server space). Development, piloting and implementation of app based (for tablets and mobile platforms) immunization monitoring system was done for MR SIA. The tablet based system for RI monitoring is in development and is expected to be completed by end December 2021. This support in data management is an ongoing activity.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">8.1 Activities supporting new vaccine introduction supported timely and with quality and serious AEFI cases fully investigated</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="8. HR (staff SSA) for immunization program -Immunization Monitoring Officer">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">WHO-IPD has been providing technical support for all activities related to new and underutilized vaccine introduction at all levels, from writing the application for Gavi support to preparation, introduction and implementation of new vaccine. In 2020, rotavirus vaccine was successfully introduced in the National Immunization Program. Further, application for typhoid conjugate vaccine catch-up campaign and introduction in routine immunization was submitted, which has been approved by Gavi and country has already received the Decision Letter. Preparation towards it is ongoing, and the activities and budget have been included in the AWPB for FY 2021/22 with WHO-IPD support. WHO-IPD provides full technical support for AEFI surveillance, from field investigation, preparation for causality assessment to technical and secretariat support to the National AEFI Investigation Committee. Reported AEFI cases have been fully investigated by SMO network, and causality assessment is done on an ongoing basis at the central level by the National AEFI Investigation Committee. Further, this support is also extended and is being conducted for the COVID-19 vaccination program, and the usual support for full AEFI surveillance is provided. This is an ongoing activity and is included in the next milestone as well.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">8.2 Activities supporting new vaccine introduction supported timely and with quality and serious AEFI cases fully investigated</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="8. HR (staff SSA) for immunization program -Immunization Monitoring Officer">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">WHO-IPD has been providing technical support for all activities related to new and underutilized vaccine introduction at all levels, from writing the application for Gavi support to preparation, introduction, and implementation of new vaccines. In 2020, rotavirus vaccine was successfully introduced in the National Immunization Program. Further, application for typhoid conjugate vaccine catch-up campaign and introduction in routine immunization was submitted, which has been approved by Gavi and country has already received the Decision Letter. Preparation towards it is ongoing, and the activities and budget have been included in the AWPB for FY 2021/22 with WHO-IPD support. WHO-IPD provides full technical support for AEFI surveillance, from field investigation, preparation for causality assessment to technical and secretariat support to the National AEFI Investigation Committee. Reported AEFI cases have been fully investigated by SMO network at field level, and causality assessment is done on an ongoing basis at the central level by the National AEFI Investigation Committee. Further, this support is also extended and is being conducted for the COVID-19 vaccination program, and the usual support for full AEFI surveillance is provided. This is an ongoing activity. In 2021, 44 serious AEFI cases related to COVID-19 vaccination and 10 serious AEFI cases related to routine immunization have been fully investigated and technical support was provided from field level to the National AEFI Investigation Committee at central level. This is a continuous activity.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">WHO : Health Information Systems (Data)</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Independent monitoring completed in further&#xA0;20 district/sub-district level (low-performing; districts and number TBD based on IM data and interventions needed) with data provided to IPCG before end June 2021.</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Strengthening/support National Immunization Program through independent monitoring to improve immunization coverage and equity">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Please see the attached description of progress</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Strengthening/support National Immunization Program through independent monitoring to improve immunization coverage and equity">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Please see the attached description of progress</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Support in data management in immunization and surveillance is provided including achievement of all data related activities in TCA. (Scaling/use of tablet based data collection tools for immunization monitoring)</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="HR (staff) for immunization program - Data assistant">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Progress is maintained in data management, data work-flow mechanisms, use of software and tools, analysis, data quality improvement, feedback, data triangulation, etc., for both VPD and immunization, and now for COVID-19 vaccination support such as for monitoring data. For VPD surveillance data, developed web-based data management system is in full use. For independent immunization monitoring, data is periodically analyzed using developed tools, and session site monitoring data for COVID-19 vaccination is periodically analyzed and shared. For rotavirus surveillance, developed surveillance data management system and database are in use, and data is checked every month for data quality and feedback is given. HMIS data for both immunization and VPD cases are analyzed periodically and feedback given. WHO-IPD disseminates VPD and immunization data summary to all relevant stakeholders every month. We have developed database for laboratory to link laboratory results and VPD clinical data in real-time and viewing in real-time by staff collecting clinical data (database completed; in discussion now for server space). Development, piloting and implementation of app based (for tablets and mobile platforms) immunization monitoring system was done for MR SIA. The tablet based system for RI monitoring is in development (as reported in Milestone 3.1). Work in this area has been supported by contractors on SSA or other forms of contract. This is an ongoing activity and is included in the next reporting milestone as well and will be reported accordingly.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="HR (staff) for immunization program - Data assistant">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Progress is maintained in data management, data work-flow mechanisms, use of software and tools, analysis, data quality improvement, feedback, data triangulation, etc., for both VPD and immunization, and now for COVID-19 vaccination support such as for monitoring data. For VPD surveillance data, developed web-based data management system is in full use. For independent immunization monitoring, data is periodically analyzed using developed tools, and session site monitoring data for COVID-19 vaccination is periodically analyzed and shared. For rotavirus surveillance, developed surveillance data management system and database are in use, and data is checked every month for data quality and feedback is given. HMIS data for both immunization and VPD cases are analyzed periodically and feedback given. WHO-IPD disseminates VPD and immunization data summary to all relevant stakeholders every month. We have developed database for laboratory to link laboratory results and VPD clinical data in real-time and viewing in real-time by staff collecting clinical data (database completed; in discussion now for server space). Development, piloting and implementation of app based (for tablets and mobile platforms) immunization monitoring system was done for MR SIA. The tablet based system for RI monitoring is in development (as reported in Milestone 3.1). Work in this area has been supported by contractors on SSA or other forms of contract. This is an ongoing activity and is included in the next reporting milestone as well and will be reported accordingly.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Quality surveillance for IBD maintaining surveillance performance indicators continued to measure impact of PCV introduction. Post-PCV introduction surveillance data including laboratory results available upto end 2020.</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Support for Invasive Bacterial Diseases sentinel surveillance">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Quality surveillance for invasive bacterial diseases (IBD) has been continued (one site). Surveillance performance indicators have been maintained, and the surveillance continues to monitor IBD burden (post-vaccine introduction for Hib and pneumococcus). Cumulative surveillance data of IBD surveillance is shared by site every month and is up to date. The site has been provided with required laboratory supplies timely (even during the pandemic). Since hospital attendance is very low due to the current pandemic, enrollment in the surveillance is also very low now as per the current situation.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Support for Invasive Bacterial Diseases sentinel surveillance">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Quality surveillance for invasive bacterial diseases (IBD) has been continued (one site). Surveillance performance indicators have been maintained, and the surveillance continues to monitor IBD burden (post-vaccine introduction for Hib and pneumococcus). Cumulative surveillance data of IBD surveillance is shared by site every month and is up to date. The site has been provided with required laboratory supplies timely (even during the pandemic). Since hospital attendance is very low due to the current pandemic, enrollment in the surveillance is also very low now as per the current situation.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Continuation of all rotavirus sentinel surveillance sites and post-introduction studies continued with data generation.</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical support for rotavirus sentinel surveillance and post-vaccine introduction surveillance, impact and effectiveness studies, and instussusception study">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Rotavirus sentinel surveillance is continued in three clinical sites with one national coordinating laboratory with technical support from WHO-IPD. Rotavirus vaccine introduction was done in July 2020, and WHO-IPD has provided technical support for this new vaccine introduction. Post-introduction surveillance of rotavirus is continued in the three clinical sites, with laboratory testing in the national coordinating laboratory.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical support for rotavirus sentinel surveillance and post-vaccine introduction surveillance, impact and effectiveness studies, and instussusception study">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Rotavirus sentinel surveillance is continued in three clinical sites with one national coordinating laboratory with technical support from WHO-IPD. Rotavirus vaccine introduction was done in July 2020, and WHO-IPD has provided technical support for this new vaccine introduction. Post-introduction surveillance of rotavirus is continued in the three clinical sites, with laboratory testing in the national coordinating laboratory.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">WHO : Data</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">3.2 Data triangulation between surveillance and immunization data (HMIS and concurrent immunization monitoring) done systematically and palika level risk matrix updated and shared</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="3.Technical support to strengthen RI and surveillance data for risk assessment to drive high coverage and equity&#xA0;by triangulating data from HMIS, VPD surveillance, concurrent RI monitoring etc.">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Continuous monitoring of HMIS (DHIS2) data has been conducted during the period for reporting rates, vaccination coverage, AEFI reporting, and vaccine-preventable diseases reporting. Reporting rate for immunization program has increased to 90.4% which is the highest of past five years for DHIS2. Administrative vaccination coverage has increased in FY 2021 for almost all antigens compared to FY 2020, and for several vaccines (pentavalent 3, fIPV 1 and 2, MR1 and MR2) the coverage is more than pre-pandemic levels. Data is triangulated between HMIS, WHO-IPD VPD surveillance data, and concurrent immunization monitoring data. Immunization monitoring is reported in Milestone 5 below. Palika level risk matrix is updated and shared and is used for monitoring. Continuous technical support and monitoring is provided to achieve high coverage. This is a continuous activity.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">11.1 Quality surveillance for IBD maintaining surveillance performance indicators continued to measure impact of PCV introduction</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="11. Support for Invasive Bacterial Diseases sentinel surveillance">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Quality surveillance for invasive bacterial diseases (IBD) has been continued (one site). Surveillance performance indicators have been maintained, and the surveillance continues to monitor IBD burden (post-vaccine introduction for Hib and pneumococcus). Cumulative surveillance data of IBD surveillance is shared by site every month and is up to date. The site has been provided with required laboratory supplies timely (even during the pandemic). Since hospital attendance is very low due to the current pandemic, enrollment in the surveillance is also very low now as per the current situation.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">11.2 Quality surveillance for IBD maintaining surveillance performance indicators continued to measure impact of PCV introduction</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="11. Support for Invasive Bacterial Diseases sentinel surveillance">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Quality surveillance for invasive bacterial diseases (IBD) has been continued (one site). Surveillance performance indicators have been maintained, and the surveillance continues to monitor IBD burden (post-vaccine introduction for Hib and pneumococcus). Cumulative surveillance data of IBD surveillance is shared by site every month and is up to date. The site has been provided with required laboratory supplies timely (even during the pandemic). This is a continuous activity.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">12.2 Preparations for post-vaccine introduction surveillance and impact studies started</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="11. Technical support for rotavirus sentinel surveillance and preparation for post-vaccine introduction impact studies">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Rotavirus sentinel surveillance is continued in three clinical sites with one national coordinating laboratory with technical support from WHO-IPD. Rotavirus vaccine introduction was done in July 2020, and WHO-IPD has provided technical support for this new vaccine introduction. Post- vaccine introduction surveillance of rotavirus is continued in the three clinical sites, with laboratory testing in the national coordinating laboratory. This is a continuous activity.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">12.1 All rotavirus sentinel surveillance sites including geographically representative expanded sites (total 3 clinical surveillance sites and one lab) fully conducting rotavirus sentinel surveillance.</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="11. Technical support for rotavirus sentinel surveillance and preparation for post-vaccine introduction impact studies">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Rotavirus sentinel surveillance is continued in three clinical sites with one national coordinating laboratory with technical support from WHO-IPD. Rotavirus vaccine introduction was done in July 2020, and WHO-IPD has provided technical support for this new vaccine introduction. Post-introduction surveillance of rotavirus is continued in the three clinical sites, with laboratory testing in the national coordinating laboratory.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">3.1 SMART tablet based tool developed and deployed for immunization monitoring</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="3.Technical support to strengthen RI and surveillance data for risk assessment to drive high coverage and equity&#xA0;by triangulating data from HMIS, VPD surveillance, concurrent RI monitoring etc.">
      <location ref="NP"></location>
     </target>
     <actual value="On Track">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">The tablet based tool for immunization monitoring is under development. This tool includes four in built-forms for data capture of immunization monitoring at district level, health facility level, immunization session level, and community level. Further, the tool includes customizable features that can be used to modify forms as per need. It includes off-line and online data capture features, GPS location, real-time dashboard features, user access features by level, immediate report generation for sharing, etc. The first demonstration of the tool by the company is scheduled in June 2021. The tool is planned to be piloted in September 2021.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">CDC Foundation : Data</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Complete first round of data cleaning</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Assessment of impact and effectiveness of rotavirus vaccine in Nepal">
      <location ref="NP"></location>
     </target>
     <actual value="Minor Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Surveillance is ongoing but out of stock ELISA kits for testing of collected specimens has delayed testing. Kits were recently procured and testing of the backlog of specimens has commenced. Testing has been slowed due to ongoing COVID-19 response activities in the country.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Assessment of impact and effectiveness of rotavirus vaccine in Nepal">
      <location ref="NP"></location>
     </target>
     <actual value="Minor Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Testing and enrollment of cases are still slowed due to earlier stock out of kits and the COVID-19 pandemic. However, the country is working to clear the backlog and once this backlog has been cleared and the data entered, data cleaning will commence.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Complete second round of data cleaning</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Assessment of impact and effectiveness of rotavirus vaccine in Nepal">
      <location ref="NP"></location>
     </target>
     <actual value="Minor Delays">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Testing and enrollment of cases are still slowed due to earlier stock out of kits and the COVID-19 pandemic. However, the country is working to clear the backlog and once this backlog has been cleared and the data entered, data cleaning will commence.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">WHO : Programme Management - LMC</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Joint supervision and monitoring completed in at least 4 districts (1 district per province X 4) before 30 June 2021</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical support for Joint supervision and monitoring of immunization program at sub-national level to drive high coverage and equity">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Through this support, staff from Government&apos;s Program Division (Family Welfare Division) visited and monitored more than 10 districts in Q4 of 2020 and 2021 till date. WHO-IPD central staff as well as field staff (SMO) conducted joint monitoring in provinces and districts along with Government staff. This mechanism has provided good support to strengthen National Immunization Program such as for supervision and monitoring of routine immunization, monitoring of catch-up activities for missed children in low-performing districts, including in the context of COVID-19 pandemic. This is an ongoing support and activity and is being conducted throughout the year.</narrative>
      </comment>
     </actual>
    </period>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Technical support for Joint supervision and monitoring of immunization program at sub-national level to drive high coverage and equity">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Through this support, staff from Government&apos;s Program Division (Family Welfare Division) visited and monitored more than 10 districts in Q4 of 2020 and 2021 till date. WHO-IPD central staff as well as field staff (SMO) conducted joint monitoring in provinces and districts along with Government staff. This mechanism has provided good support to strengthen National Immunization Program such as for supervision and monitoring of routine immunization, monitoring of catch-up activities for missed children in low-performing districts, including in the context of COVID-19 pandemic. This is an ongoing support and activity and is being conducted throughout the year.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">WHO : Financial/General Management</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">4.1 Monitoring and evaluation central core group formed and standardization of monitoring formats prepared and adapted as per program needs (e.g. including IPC practice monitoring at RI sessions).</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="4. Technical support for Joint supervision and monitoring of immunization program at province, district, health facility and immunization session levels to drive high coverage and equity">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
      <comment>
       <narrative xml:lang="EN">Through this support, staff from Government&apos;s Program Division (Family Welfare Division) visited and monitored more than 20 districts in Q4 of 2020 and 2021 till August 2021. September to December 2021 monitoring is ongoing and is expected to be completed in at least 4 districts. WHO-IPD central staff as well as field staff (SMO) conducted joint monitoring in provinces and districts along with Government staff. This mechanism has provided good support to strengthen National Immunization Program such as for supervision and monitoring of routine immunization, monitoring of catch-up activities for missed children in low-performing districts, including in the context of COVID-19 pandemic. This is an ongoing support and activity and is being conducted throughout the year. The central core group is the immunization program core group.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">University of Oslo : Data</narrative>
   </title>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">1. EPI digital package installed
2. Data quality app installed
3. EPI legacy data migrated
4. Training given</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Support transitioning to DHIS2 for EPI">
      <location ref="NP"></location>
     </target>
     <actual value="Completed">
      <location ref="NP"></location>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="5">
    <title>
     <narrative xml:lang="EN">Transition plan for EPI in place with agreed date for end of parallel system
Costed scale up plan exist</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-12-31"></period-end>
     <target value="Support transitioning to DHIS2 for EPI">
      <location ref="NP"></location>
     </target>
     <actual>
      <location ref="NP"></location>
     </actual>
    </period>
   </indicator>
  </result>
 </iati-activity>
</iati-activities>
